HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Blood Glucose Health Claim For Dietary Supplement Set For UK Assessment

Executive Summary

Ascarit is seeking UK approval for the health claim “clinically proven in assisting healthy blood glucose levels” in the target population of type 2 diabetics for its white mulberry-based dietary supplement. It will be just the second claim assessed by the UK Nutrition and Health Claims Committee which took over the role from EFSA on 1 January 2021 following Brexit.

You may also be interested in...

US Supplement Firms Warned About Offering Menu Of Disease Treatments, Topped By Diabetes

Three weeks after warning 10 firms, FDA publishes warnings identifying diabetes claims firms in New York and Tennessee; in August, it found so many violative claims by firms in Idaho and Oregon it might have been more efficient to identify diseases their products weren’t promoted to treat.

UK Plan To Replace EFSA Post-Brexit Leaves Industry With Unanswered Questions

With the deadline looming for the UK to strike a Brexit agreement, industry groups Food Supplements Europe and CRN UK give their reactions to government plans to create a new Nutrition and Health Claims Committee to take on the role of EFSA in the event of a no deal.

UK To Overhaul Health Claims Approval In Event of 'No Deal' Brexit

In the event of a no deal Brexit, new health claims approved by EFSA will not be valid in the UK. Firms will need to seek approval from the new UKNHCC body.


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts